700 Children's Drive
- Actin interacting proteins and miR-17~92 cluster as therapeutic target(s), biomarker(s) of disease progression and diagnostic tool(s) for childhood and adult cancers. In particular differential subcellular localization of VASP, pVASP-S157, pVASP-S239, profilin1, cofilin1, vimentin and gelsolin in association with miR-17~92 cluster expression as regulators actin dynamics mediated apoptosis and metastasis of cancer cells is under investigation. Moreover, I am also investigating the therapeutic potential of DHA against cancer survival and metastasis.
- Actin interacting proteins as therapeutic target(s) and biomarker(s) of placental invasion deformities like accreta, eclampsia and choriocarcinoma. In particular the role of VASP, pVASP-S157, pVASP-S239, profilin1, cofilin1, vimentin and gelsolin as regulators of actin dynamic mediated trophoblast invasion is under investigation. Investigations are also exploring the therapeutic potential of oxygen supplementation and DHA against hyper invasion placental disorders.
- Actin interacting proteins as therapeutic target(s) and biomarker(s) of PAHs and BPD. In particular the role of VASP, pVASP-S157, pVASP-S239, profilin1, cofilin1, as regulators of actin dynamic mediated early changes in angiogenesis, alveolar simplification and epithelial proliferation under the effect of maternal inflammation and hyperoxia in neonatal lung developmental is under investigation. The second objective of this project is to study how these early alterations are linked with the development of adolescent PAH and BPD.
- To investigate the DHA effect on LPS induced maternal infection transmitted inflammation causing neonatal lung developmental deformities under hyperoxic conditions. The goal of this project is to identify the mechanisms associated with decreased inflammation in response to DHA supplementation, specifically focusing on Notch signaling mediated chromatin remodeling. In particular Notch signaling is under investigation in regulation of maternal inflammation induced lung developmental deformities in preterm babies.
- Mehboob Ali has studied cancer cell biology and therapeutics for 5+ years and has authoredmore than 19 peer-researcharticles including book chapter.
- He has served as a reviewer for the peer reviewed Internationally recognized journals.
- Ali is a member of the several professional bodies including AACR, ATS, and ASCO and acted as a judge for poster session in scientifi c meetings.
- He has served as a borad member of postdoc research symposium (PRS) committee in between 2010-2013 and also as a senior vice president of Jefferson Postdoc Association (JPA) in between 2010-2013 at Thomas Jefferson University, Philadelphia.